Search Results

You are looking at 1 - 10 of 103 items for :

  • "BRAF V600E mutation" x
Clear All
Free access

F Frasca, C Nucera, G Pellegriti, P Gangemi, M Attard, M Stella, M Loda, V Vella, C Giordano, F Trimarchi, E Mazzon, A Belfiore and R Vigneri

favors BRAF (V600E) mutation. Several studies tried to establish a correlation between BRAF (V600E) and the clinical features of PTCs, but results have been controversial ( Lee et al . 2007 , Xing 2007 ): in some studies, BRAF (V600E) was

Free access

Peng Hou, Dingxie Liu and Mingzhao Xing

). Given the importance of this epigenetic aberration in thyroid tumorigenesis, we hypothesize that the BRAF V600E mutation, through activating the MAPK pathway, may aberrantly affect gene methylation in thyroid cancer, as a molecular mechanism in BRAF

Free access

Rengyun Liu and Mingzhao Xing

. Association of TERT promoter mutations with BRAF V600E mutation in thyroid cancer BRAF V600E is the most common oncogene in thyroid cancer that plays a fundamental role in the tumorigenesis and progression of thyroid cancer, particularly PTC ( Xing 2005

Free access

Rengyun Liu and Mingzhao Xing

), and galectin 3 ( Bartolazzi et al . 2008 ) and prognostically BRAF V600E mutation ( Xing et al . 2013 b , 2014 a ). However, the diagnostic and prognostic accuracies of these markers still have much room for improvement and new markers are

Open access

Zongjing Zhang, Dingxie Liu, Avaniyapuram Kannan Murugan, Zhimin Liu and Mingzhao Xing

Introduction BRAF V600E mutation is the most common genetic alteration in thyroid cancer, particularly papillary thyroid cancer (PTC; Xing 2005 ), and plays an important role in thyroid tumorigenesis through aberrantly activating the RAS

Free access

Xiaoli Liu, Justin Bishop, Yuan Shan, Sara Pai, Dingxie Liu, Avaniyapuram Kannan Murugan, Hui Sun, Adel K El-Naggar and Mingzhao Xing

tumorigenesis. Melanomas and follicular cell-derived thyroid cancer share considerably similar genetic backgrounds; for example, they both harbor the BRAF V600E mutation with a high prevalence ( Davies et al . 2002 , Xing 2005 a ). We were, therefore

Free access

Matthias S Dettmer, Anja Schmitt, Hans Steinert, David Capper, Holger Moch, Paul Komminoth and Aurel Perren

times their widths.’), and the percentage of tall cells (TCs) needed in a given tumor is defined variably in the literature ( Ostrowski & Merino 1996 , DeLellis et al . 2004 ). The oncogenic BRAF V600E mutation occurs in about 40–45% of PTCs

Free access

Min-Hee Kim, Ja Seong Bae, Dong-Jun Lim, Hyoungnam Lee, So Ra Jeon, Gyeong Sin Park and Chan Kwon Jung

Introduction The V600E BRAF mutation is the most common genetic alteration in papillary thyroid carcinoma (PTC). The prevalence of the BRAF V600E mutation varies according to the histological subtype; the mutation is frequent in the tall cell

Free access

Branca M Cavaco, Pedro F Batista, Carmo Martins, Ana Banito, Francisco do Rosário, Edward Limbert, Luís G Sobrinho and Valeriano Leite

age of diagnosis of familial PTC with the BRAF -V600E mutation with that of sporadic PTC with the mutation. Comparison between the two groups was performed using the unpaired t -test. The difference between the two means was considered significant at

Free access

Xiaopei Shen, Rengyun Liu and Mingzhao Xing

relationship between TERT and BRAF V600E or RAS mutations in the subsets of RAS mutation- or BRAF V600E mutation-negative patients, respectively. In the RAS mutation-negative patients, BRAF V600E mutation was still significantly associated with